|Articles|August 9, 2021
- Pharmaceutical Executive-08-01-2021
- Volume 41
- Issue 8
Pharmaceutical Executive, August 2021 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive August 2021 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 5 years ago
Why the Pandemic is Rewriting the Biopharma Rule Bookabout 5 years ago
Primary Care in Crisis: PCP Navigation in a Specialty Worldabout 5 years ago
A Brave New World: Optimizing Access in Wake of COVIDabout 5 years ago
By Any Genes Necessary: The Role of MEAs for Gene Therapiesabout 5 years ago
A Framework for Future: Strengthening Market Access Competenciesabout 5 years ago
A Global Vision for Accessabout 5 years ago
Early Payer-Related Lessons for Pharma Post-Aduhelm Approvalabout 5 years ago
Biotech Capital Markets Continue to UnderperformAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Artisan Partners’ Director Calls for Novartis Board Shake-Up
2
The Agentic AI Revolution in Biopharma
3
340B Under Pressure: Inside Pharma's Push for Greater Clarity
4
Kura Oncology Spins Out Caspian Therapeutics With $50 Million to Test Menin Inhibition as a Disease-Modifying Approach to Diabetes
5